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1. Introduction 
The management of severe sepsis and septic shock remains to this day one of the great 
challenges in medical care. These two disease entities represent significant morbidity and 
mortality and cross the threshold of multiple medical disciplines. Worldwide it is estimated 
that one in ten intensive care unit (ICU) patients carry the diagnosis of severe sepsis (1). For 
the year 2020, in the United States alone, the projected number of severe sepsis cases will 
approach 1.1 million (2). These disease entities are not only common, but lethal. Severe 
sepsis carries a reported mortality of 28% (2). Septic shock has recorded mortality rates as 
high as 60% (3). 
Sepsis has a strong association with respiratory failure. From an epidemiologic perspective, 
sepsis and pneumonia are the leading causes of acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS) (4-5). Reported sepsis-related ARDS incidence levels 
range from 16%-73% in multiple case series (6-9). Pneumonia is consistently documented as 
the primary inciting infection in the sepsis literature (10-13).  
Severe sepsis and septic shock place critically ill patients at risk for respiratory failure and 
endotracheal intubation. In addition to epidemiologic evidence, there are multiple known 
complex physiologic variables in sepsis that explain the high potential risk for respiratory 
failure (14). Sepsis alters the respiratory drive. Early sepsis is particularly associated with an 
increase respiratory rate and an increase in coinciding energy expenditure. Components of 
sepsis-related ventilatory failure include a combination of increased respiratory muscle 
energy requirements with decreased energy availability and impending respiratory muscle 
fatigue (14).  
Additional contributing factors to sepsis-associated respiratory failure include the 
interaction between the pulmonary and the cardiac system (14). Sepsis decreases pulmonary 
dynamic compliance, which leads to an increased in pleural pressure variation with each 
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breath. This change in variation can augment right atrial venous return. A volume-
resuscitated patient with sepsis will exhibit a significant increase in right atrial filling 
pressure. This increased return on the right side can translate to left-sided cardiac 
dysfunction and contribute to pulmonary edema and cardiac dysfunction (14). Other 
pulmonary-cardiac interactions include decreased left ventricular dysfunction due to 
pleural pressure changes. These changes effectively increase cardiac afterload. There is also 
the added phenomenon of intrinsic myocardial depression that is associated with septic 
shock (15). The preceding mechanisms for respiratory failure are significant. As severe 
sepsis and septic shock is a highly complex entity, these physiologic variables are a few of 
many contributory factors.  
As demonstrated, severe sepsis and septic shock place a critically ill patient at high risk for 
respiratory failure. Correction of this impending failure may require endotrachael 
intubation. The decision to intubate and ventilate these patients presents significant 
obstacles as well. Severe sepsis and septic shock patients have potential complex multi-
organ dysfunction issues that can create clinical care difficulties before, during, and after the 
intubation procedure. The choice of pharmacologic agent to facilitate endotracheal 
intubation should reflect these challenges in care.  
2. Intubation in severe sepsis and septic shock 
Endotrachael intubation for severe sepsis and septic shock presents multiple hurdles. Prior 
to intubation, critically ill patients with severe sepsis and septic shock are likely hypoxic. 
The septic patient is at high risk for oxygen desaturation during the procedure. Figure 1 
illustrates the oxyhemoglobin curve and associated desaturation risk based on initial 
starting oxygen saturation (16). The previously described variables such as increased 
respiratory effort; increased energy expenditure and respiratory muscle fatigue further 
increase risk of desaturation despite appropriate maneuvers such as pre-oxygenation (16). 
Figure 2 further illustrates the effect of critical illness and body habitus on time to oxygen 
desaturation (17).  
Critical illness can further decrease time to profound hypoxia beyond these described 
desaturation curves (16). Additional desaturation risk can ensue in cases of delayed 
intubation due to a difficult airway situation. Overall, endotrachael intubation in critically ill 
patients outside the operating environment is associated with high morbidity and 
complications (18-20). 
The change from negative to positive pressure with intubation and mechanical ventilation 
represents significant changes in patient hemodynamics. One of the most common 
hemodynamic changes associated with endotracheal intubation is hypotension. Some 
studies have reported hypotension occurring in up to 25% of emergency intubations (21).  
One notable difficulty element is the associated decrease in venous return with intubation. 
Venous return reduction occurs from several mechanisms (21). Venous return is a function 
of the difference of systemic pressure subtracted from right atrial pressure. Vasodilation 
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from induction agents and reduction of catecholemine-associated vascular tone reduce left 
sided pressures and venous return. Positive pressure ventilation abruptly increases right 
atrial pressure. Decreased systemic pressure and increased right atrial pressure create a 
reduction in venous return that is difficult for a critically ill patient to compensate. Ongoing 
increased right atrial pressure contributing to persistent decreased venous return will 
translate to decreased left ventricular preload (22).  
 
Figure 1. Oxyhemoglobin curve displays risk categories of desaturation (16) 
Positive pressure ventilation can further affect left ventricular preload due to the 
phenomenon of interdependence between the right and left ventricle (22). The increase in 
thoracic pressure can lead to an increase in pulmonary vascular resistance. This situation 
results in decreased right ventricular ejection and increasing right ventricular end diastolic 
volume. Increased right end diastolic volume translates into decreased left end diastolic 
volume and preload. Mechanical ventilation exerts multiple effects on the cardiopulmonary 
system that need to be considered when initiating endotracheal intubation. The situation is 
further complicated in light of the pre-existing cardiopulmonary abnormalities of the sepsis 
patient (15). 
Endotracheal intubation in the severe sepsis and septic shock patient poses many 
physiologic difficulties. These processes need to be heeded when deciding to intubate and 
choosing agents to facilitate the procedure. 
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Figure 2. Time to desaturation when apneic with respect to size and medical condition (17) 
3. Choosing an induction agent to facilitate intubation 
The critically ill severe sepsis and septic shock patient in respiratory failure experiences 
many physiologic changes. These changes need to be addressed when evaluating the 
properties of intended induction agents. 
As stated, this critically ill population is at high risk for oxygen desaturation. Time of onset 
for expected effect needs to be considered. An ideal agent would have a short onset of action 
to prevent undo delay in the procedure. It has been reported that a critically ill patient could 
theoretically experience serious oxygen desaturation within 23 seconds of apnea (23). This 
risk of desaturation needs to be evaluated in cases where a paralytic agent in conjunction 
with an induction agent is the planned intubation strategy. 
Septic shock patients are hemodynamically unstable. By definition these patient have fluid-
refractory hypotension (24). Induction agents that further contribute to this instability need 
to be carefully reviewed. The use of induction agents that decrease cardiac output or cause 
further dilation should be carefully contemplated prior to use. Severe sepsis and septic 
shock have a documented incidence of myocardial depression (15). Some induction agents 
may potentiate this cardiac depression as well. 
Metabolism of induction agents needs to be examined as well. Severe sepsis and septic 
shock can exhibit associated organ dysfunction that will potentially affect induction agent 
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metabolism (25). Organ injury that needs to be especially regarded includes renal and 
hepatic dysfunction. 
4. Review of available induction agents 
4.1. Etomidate 
Etomidate is a non-barbiturate imidazole compound used for induction in endotracheal 
intubation. The primary mechanism of action is direct action on the gamma amino butyric 
acid (GABA) receptor (26). As a sedative hypnotic agent, it exhibits many favorable 
properties that make it a particularly attractive agent to facilitate intubation. Etomidate has a 
rapid reliable mechanism of action and duration; has minimal affect on many cardiovascular 
parameters; is neuroprotective and has other favorable attributes as well. 
Etomidate is typically dosed at 0.3 mg/kg in adult patients (27). Reported literature dosing 
for induction is cited as 0.2-0.4 mg/kg (28). It is also recommended to consider a reduction in 
dosing in the elderly patient due to delayed metabolic clearance (28). 
As stated, etomidate has a rapid onset and duration of action with a single bolus dose. In a 
standard single induction dose, onset to hypnotic effect is 5-15 seconds (28). Duration of 
action is rapid as well and is dose dependent. Estimated metabolism is 5-14 minutes. 
Metabolism of the medication is primarily hepatic and the agent is strongly protein bound. 
Interestingly, hepatic disease and protein metabolism may alter potency of etomidate, but 
not timing of clinical actions (28). 
The strength of etomidate lies in its cardiovascular effects. Etomidate does not significantly 
impact systolic blood pressure (SBP), mean arterial blood pressure (MAP), central venous 
pressure (CVP), heart rate, systemic vascular resistance (SVR), cardiac index (CI), stroke 
volume (SV) in standard bolus dosing (28). The literature in some cases does report a slight 
decrease in SBP. At high bolus dosing (>0.4mg/kg), one recorded study reports less than a 
15% impact on SBP and MAP (29). Etomidate does not adversely alter hemodynamics in the 
face of valvular or coronary artery disease (28). The literature also reports improvement of 
coronary blood flow with the use of etomidate without an increase in oxygen consumption 
(30). Etomidate seems to offer a significant safety profile for hemodynamically compromised 
patients. 
Other advantageous elements of etomidate include its neuroprotective effects. Etomidate is 
noted to effectively lower intracranial pressure (ICP) (28). Etomidate is able to lower ICP 
without adversely affecting hemodynamics. In addition, etomidate appears to 
independently lower cerebral oxygen consumption by several mechanisms (28). The 
medication also has the ability to lower intraocular pressure. This induction agent again has 
many attractive properties when considering its use. 
Adverse effects of etomidate should be reviewed. Etomidate is linked to myoclonus. 
Reported rates of this effect can be as high as 30% (28). The literature regarding this agent 
and seizures remains mixed (28). There have been reports of decreased seizure potential in 
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patients with seizure disorders. Overall, etomidate remains a neuroprotective agent. The 
induction agent has a moderate risk of nausea and vomiting. This may be a consideration in 
the non-fasted patient. Etomidate also may have a potential to cause peripheral vascular 
irritation (28). 
The critical care community appropriately expressed concerns about etomidate in regards to 
its link to critical illness-related corticosteroid insufficiency. Etomidate has a documented 
ability to inhibit the function of the 11 β-hydroxylase enzyme and subsequently contribute 
to this phenomenon (31-32). Several retrospective studies or study subsets have even 
suggested a mortality impact from this suppressive action (33-36).  
The literature clearly acknowledges and supports the presence of etomidate-related adrenal 
insufficiency. The presence of actual mortality remains questionable. Multiple studies 
retrospective and prospective do not support the presence of increased mortality. Ehrman 
and Dmello exhibited a lack of mortality in large retrospective cohort studies (37-38).  
Prospective studies surrounding the use of etomidate remain encouraging in regards to 
mortality. Tekwani initially showed no difference in mortality in a prospective observational 
study of over 100 septic patients receiving etomidate (39). The same author performed a 
prospective randomized study of etomidate versus midazolam in septic patients, which did 
not show any increase in length of stay with use (40). A large randomized prospective study 
comparing etomidate to ketamine in over 400 critically ill patients failed to show a mortality 
difference between the two agents in regards to administration (41). It should be noted that 
only 16% of patients in this large cohort carried the diagnosis of sepsis.  
Due to the presence of adrenal insufficiency, there is consideration in regards to addition of 
corticosteroid therapy to patients receiving etomidate. Initial research suggests that in non-
shock states this approach may not be effective. A recent prospective study by Payen, et al 
revealed no significant difference in 28 day mortality, ICU length of stay, ventilator days, or 
organ failure scales between etomidate treated patients who received moderate dose 
steroids and those who received a saline control (42). Use of steroids likely should be 
reserved for septic shock patients with fluid and vasopressor refractory shock (24). 
Etomidate remains an attractive induction agent for severe sepsis and septic shock patients. 
It has a rapid reliable onset and duration of action, which is critical in a highly unstable, 
hypoxemic patient. The hemodynamic profile is ideal in the setting of hemodynamic 
instability and potential anticipated clinical decompensation. Vulnerable elderly patients 
with co-morbidities seem less susceptible to injury with this agent. It has added beneficial 
effects that do not contribute to potential worsening organ failure. 
The issue of adrenal insufficiency continues to give emergency and critical care practitioners 
pause in regards to use. Based on the most current literature, the corticosteroid insufficiency 
issue should be acknowledged and respected. At the same time, the current literature does 
not support an absolute mortality effect. As the intubation procedure under non-operative 
circumstances can be associated with complications, this reliable medication that preserves 
hemodynamic reflexes should remain in the induction armamentarium. 
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4.2. Midazolam 
In reviewing available induction agents, midazolam should be included as an option. 
Midazolam is a member of the benzodiazepine class of medications. As with other 
benzodiazepines, the medication possesses sedative, hypnotic, amnestic, and anti-anxiolytic 
properties. The drug specifically is classified as an imidazobenzodiazepine (43). Due its 
unique structure, midazolam has a significantly rapid onset and short duration of action. 
These qualities make it an attractive induction medication.  
As a benzodiazepine agent, midazolam exerts its influence on the GABA receptor. 
Midazolam binds to the GABA receptor and potentiates the inhibitory affect of GABA on 
the receptor (43). 
Typical rapid sequence dosing is 0.1-0.3 mg/kg. Onset of action in intravenous dosing is 30-
60 seconds. Duration of action is 15-30 minutes (43-45). The lipophilic nature of this drug 
accounts for its rapid uptake and onset of action. Its rapid metabolism and elimination are 
subject to several factors. 
Midazolam is metabolized through the hepatic system. The cytochrome P450 system is the 
primary actor in midazolam breakdown. Cytochrome P450-3A4 hydroxylates midazolam to 
its metabolites, which are ultimately renally excreted (43). This makes midazolam metabolism 
subject to agents that may interfere with the cytochrome P450 system. Patients taking such 
agents as ranitidine or macrolide antibiotics may experience a decreased clearance of the 
medication (43). As elimination is through the renal system, patients with kidney dysfunction 
may experience a longer sedation period due to slower elimination time (43). 
As an induction agent, midazolam has several favorable properties. The rapid action of this 
medication is a clear advantage. Critically ill patients have a very small respiratory and 
ventilatory reserve. Rapid action is crucial. The agent has anticonvulsant and muscle 
relaxant activity. The pharmacology literature has reported that midazolam directly relaxes 
the muscles of the airway (43). As endotrachael intubation requires optimum conditions, 
muscle relaxation presents a clear advantage. Midazolam as an agent is also not linked to 
vomiting and does not have a peripheral vascular irritant effect (45). 
Midazolam does have noted cardiovascular effects. Use of midazolam will decrease both 
systolic and diastolic blood pressure (45). The primary mechanism appears to be vascular 
dilation and reduction of systemic vascular resistance (SVR) (45). This results in an increase 
in heart rate as part of the baroreceptor response. Clinicians should expect a lowering of 
blood pressure and an increase in patient heart rate with the use of this drug. Cardiac index 
is preserved (45). The degree of blood pressure reduction is not dependent on the presence 
of cardiac disease, but is more pronounced in cases of volume depletion (45).  
The hypotensive effect of midazolam needs to be seriously scrutinized. A case series in the 
literature revealed at least a 10 percent reduction in systolic blood pressure in patients 
receiving midazolam for intubation (46). The reduction in blood pressure was doubled for 
patients age 70 years and older. Reduction in dose still precipitated hypotension in this 
report (46).  
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As endotracheal intubation physiologically predisposes a patient to hypotension, 
midazolam may not be the best induction agent for the severe sepsis and septic shock 
population. This patient population is often volume depleted and hypotensive prior to the 
procedure. Midazolam carries the risk of worsening an already tentative hemodynamic 
situation. Clinician should strongly consider alternative induction agents for this critically ill 
population. 
4.3. Ketamine 
Ketamine is a medication with a unique mechanism of action. Due to its many 
advantageous properties, this agent merits discussion. Structurally, ketamine resembles the 
hallucinogenic agent phencyclidine (PCP) (47). Ketamine acts as a dissociative agent. The 
medication essentially dissociates the thalamus from the limbic system. It is different from 
the previously discussed agents in that it does not interact with GABA receptors. Its primary 
mechanism of action is its antagonist effect on the excitatory N-methyl-D-aspartate receptor 
(NMDA) (48). Ketamine also interacts with opioid and muscarinic receptors, which 
contribute to its unusual qualities and effects (48). These qualities include sedative, 
hypnotic, analgesic, bronchodilator and cardiac stimulatory effects. 
Dosing of ketamine for induction of intubation is typically 1-2 mg/kg (27,49). The sedative 
effects are rapid and initiate in approximately 30-60 seconds (27,48-49). Primary sedative 
effects dissipate within 10-15 minutes. 
Ketamine is metabolized in the liver and excreted in urine (47). The primary mechanism of 
breakdown is through the cytochrome P450 system. Of note, decreased renal function does 
not effect duration of action as active ketamine metabolites are not excreted in the urine 
(47,51). Limited ketamine use for induction should not be impacted by renal disease. 
Induction doses of ketamine have not been well studied in severe liver disease. It is thought 
that a transient  induction dose in liver dysfunction should not have a significant clinical 
impact (51). Certain medications can interfere with ketamine metabolism including 
diazepam and halothane (47). Prolonged use of ketamine is linked to elevation of liver 
enzymes (47). 
As stated, ketamine has many favorable effects as an induction agent. It has a rapid onset 
and duration of action. In a potentially difficult, tenuous airway, where timing is critical, 
this is an important property. Ketamine has the unique ability to increase blood pressure. It 
is an actual cardiovascular stimulant (47). Ketamine increases heart rate, blood pressure and 
systemic vascular resistance (SVR) (47). Ketamine acts to increase these parameters through 
direct central stimulation of the autonomic nervous system and through indirect inhibition 
of catecholamine uptake (47, 52).  
Unlike other agents, ketamine is not linked to hypotension. As the severe sepsis and septic 
shock patient is at high risk for hemodynamic instability, this stimulatory effect can be 
valuable. Ketamine has been reported to show a positive inotropic action. This property 
may be an advantage, as septic patient tend to have myocardial suppression (15). With 
increased cardiovascular stimulation, comes increased myocardial oxygen demand. 
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Clinicians will need to balance ketamine use in the setting of coronary artery disease (47). 
Overall, ketamine increases mean arterial pressure (MAP), SVR, and cardiac index (CI) (47-
48,51-52). 
Ketamine exhibits other pertinent abilities that merit consideration. Ketamine preserves 
airway reflexes and thus minimizes aspiration (51). Ketamine is a known bronchodialtor 
(47,49,51). In a high-risk airway or a patient with respiratory co-morbidities, these properties 
can give a care provider an additional benefit. In addition, ketamine has direct analgesic 
action, which may contribute to patient care during an uncomfortable procedure. 
Ketamine has neurologic actions, which have generated controversy. Ketamine has both 
epileptic and anti-epileptic effects. Ketamine has been noted to change EEG patterns to 
match epileptiform patterns (47). At the same time, evidence of seizure causation is limited 
and even contradicted in the literature (53-54). Ketamine’s impact on intracranial pressure 
has generated additional controversy. Initial early ketamine literature did report an increase 
intracranial pressure (47). A more recent literature review challenges these early reports and 
suggests a possible neuroprotective role for ketamine (55).  
Ketamine does have adverse actions that need to be evaluated. Ketamine is associated with 
increase oral and airway secretions (47). The clinician needs to consider premedication with 
atropine or glycopyrrolate to counteract this effect. Ketamine does have a small independent 
risk factor for larnygospasm. The mechanism seems to be linked to airway sensitivity. 
Ketamine preserves airway reflexes and may cause increase airway responsiveness to 
secretions (56). Ketamine is connected to a phenomenon known as reemergence. Patients 
can experience hallucinations, alarming dreams and delirium. As the patient will be 
intubated, this phenomenon is less significant. It is also attenuated by concomitant 
benzodiazepines. Ketamine is associated with nausea and vomiting (51).  
In review of ketamine, this medication is an option for severe sepsis and septic shock. It is 
rapidly acting with a short period of duration. Metabolism does not appear to be a 
significant concern. It preserves airway reflexes in a potentially high-risk situation. Unlike 
several agents, it does not cause hypotension. It is linked directly to an increase in blood 
pressure. This is of particular benefit in hypotensive, hemodynamically unstable patients. 
Ketamine has been shown to specifically improve hemodynamics in a septic shock case 
history (57). In a large, randomized, blinded study, ketamine and etomidate were both 
shown to have a comparable safety profile in critically ill patients (41). This particular cohort 
of over 400 patients included approximately 16% septic individuals. Clinicians do need to 
balance known adverse effects such as increased secretions and myocardial oxygen demand. 
4.4. Propofol 
Propofol is a unique induction mediator. It is an alkyl phenol with sedative, amnestic and 
anesthetic properties (58). Of note, propofol is highly water-insoluble. This necessitates that 
its commercial preparation dissolve the medication in a lipid emulsion consisting of soybean 
oil, egg lecithin and glycerol (59). Despite the egg component in the emulsion, current expert 
consensus does not indicate that an egg allergy prohibits the use of propofol (59).  
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At the same time, the lipophilic nature of this unusual drug contributes to its rapid onset and 
offset of activity (60). Propofol aptly crosses the blood brain barrier to exert its sedating effect. 
Propofol primarily acts on the GABA receptor and potentiates its activity (50). Induction 
dosing of propofol ranges from 1.5-3 mg/kg (58). Propofol initiates sedative effects within 20-
40 seconds on intravenous administration . Duration of action is 5-10 minutes (58, 60-61).  
Metabolism of propofol is through hepatic conjugation (60). The medication is renally 
excreted. It should be noted that chronic renal or hepatic insufficiency do not significantly 
affect propofol pharmacokinitcs. The use of prolonged propofol use has not been tested in 
these populations. The metabolism and elimination of propofol has also not been well 
studied in cases of acute renal or hepatic failure (58, 60). 
There are certain populations to consider when adjusting dosing with propofol. Patients 
greater than 60 years old have a documented decreased clearance of the drug (58,60). This 
decreased elimination is thought to be secondary to decreased cardiac output and hepatic 
blood flow. The obese patients can present a challenge when using this medication as well. 
Propofol has an increased saturation in fatty tissue and a subsequent decrease in plasma 
clearance. Use of propofol in obese patients should be dosed according to ideal body weight 
in the obese patient to insure safety (60). 
Propofol as an induction medication has attractive attributes. Its rapid onset of action and 
short duration of action is a definite benefit for the unstable patient who requires intubation. 
It also does not seem to be affected by chronic renal or hepatic insufficiency. Propofol has a 
known bronchodilator ability and has been used in patients with chronic obstructive 
pulmonary disease with success (60). Propofol also has anti-emetic properties as well (62). 
Such qualities suggest propofol has good potential as an induction drug. 
For a patient with neurologic injury, propofol offers neuroprotective effects. Propofol has 
been shown to either maintain or reduce intracranial pressure in patients with neurologic 
injury (60). The medication also has been shown to improve cerebral auto-regulation. 
Propofol does have certain qualities that limit its use. Propofol significantly reduces blood 
pressure. Studies have shown that propofol can reduce blood pressure 30% from baseline 
(58). Propofol exhibits this suppressive effect to a greater degree than other induction agents 
including certain barbiturates and midazolam (58, 60). The reduction in blood pressure is 
presumed to be due to a decrease in systemic vascular resistance and cardiac contractility 
(60). Propofol also reduces heart rate despite the reduction in blood pressure. The 
medication has been linked to prolonged bradycardia (58). Elderly patients seem to be 
particularly susceptible to these effects. Research has shown a decrease in cardiac index in 
elderly surgical patients who received propofol (58). These effects will give the clinician 
pause when approaching the hemodynamically unstable, volume depleted, or elderly 
patient. As severe sepsis and septic shock patients can  potentially be included in such 
categories; propofol appears to be a less ideal medication. 
Propofol appears to impact the immune system. The lipid emulsion component of propofol 
has been shown to have some suppressive affect on the immune system (60). Propofol in one 
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study exhibited inhibitory effects on neutraphil function (62). Of note, the effect appears to 
be more significant in cases of prolonged infusion. 
Propofol has additional issues to address. Though transient, propofol does cause pain at the 
site of injection. If a propofol infusion is used after induction, the phenomenon of propofol 
infusion syndrome needs to be considered. Propofol infusion syndrome is an often-fatal 
entity that consists of metabolic acidosis, renal failure, cardiac failure and rhabdomyolysis. 
It is linked to prolonged propofol infusion at higher doses. The disease also is connected to 
pressor and steroid use in conjunction with propofol (64). This problem will not affect short-
term induction use. The clinician does need to be mindful that initiating a propofol infusion 
may be detrimental to a sepsis patient who may later require vasopressors or steroids. 
In general, the unfavorable hemodynamic profile displayed by propofol does not make it an 
ideal mediator for intubation in severe sepsis and septic shock patients. The negative effects 
likely outweigh its rapid action and other positive attributes. This is especially pertinent in 
the light of the hemodynamic changes induced by endotracheal intubation itself. 
4.5. Thiopental and methohexital 
Thiopental and methohexital are barbiturate sedative induction agents. Due to their rapid 
onset of action, these two medications are classified as ultra short acting. As barbiturates, 
thiopental and methohexital exhibit their effect at the level of the inhibitory GABA receptor 
(50). Thiopental also may have a secondary mechanism of inhibiting the NMDA receptors 
(50). These processes lead to the expected effect of sedation.  
Typical induction dose for thiopental is 3-5 mg/kg (50,65). Methohexital is usually dosed at 
1-2 mg/kg (50,66-67). Both agents have a swift onset of action at 10-30 seconds (50). 
Thiopental is rapidly metabolized and has a duration of  5-10 minutes (50). Methohexital is 
metabolized 3-4 times more quickly than thiopental and has a duration of action of 4-7 
minutes (50,68). The duration of action is comparable despite the faster metabolism of 
methohexital. This originates from the fact that actual clinical effect is due to redistribution 
of the medication in the body. In both agents, redistribution to other tissues is swift (50). 
Metabolism of both these barbiturates is hepatic with renal elimination. Due to a balance in 
clearance and elimination, renal insufficiency does not seem to impact thiopental dosing or 
duration of action. Of note, phenobarbital is one of the few barbiturates affected by renal 
dysfunction. Plasma clearance of thiopental also remains unaffected by cirrhosis or 
decreased hepatic blood flow (65). There are factors that do impact duration of action and 
dosing. Decreased clearance of thiopental in elderly patients indicates a reduction in dose 
for expected onset of effect. Some authors recommend a reduction in dose of 25-50% for 
older individuals. Half-life of thiopental is increased in younger females and obese 
individuals (65). 
As an induction drug, both thiopental and methohexital have a rapid onset and short 
duration of action. These qualities make these medications potential options for critically ill 
patients with a need for rapid airway management. Thiopental has significant 
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neuroprotective effects as well. The medication has been shown to decrease intracranial 
pressure, cerebral oxygen demand , and to decrease the actions of damaging neuro-
excitatory transmitters (65). Critically ill patients with brain injury may reap the reward of 
these beneficial actions. 
Thiopental and methohexital do have a marked negative impact on the cardiovascular 
system. Thiopental has been shown to profoundly lower mean arterial pressure and cardiac 
output (65). The primary mechanism appears to be vasodilatation. The negative inotropic 
effect is not entirely defined. There also tends to be a resulting increase in heart rate. 
Increased heart rate can negatively impact an already tachycardic septic patient or a patient 
with coronary artery disease. These agents do not appear to offer any benefit to the 
hemodynamically unstable or volume depleted patient. 
There are added negative aspects of barbiturates as induction agents for septic patients. The 
barbiturates appear to impact immunosuppression. Both thiopental and methohexital were 
linked to inhibition of granulocyte recruitment and phagocytosis (69). Thiopental has also 
been linked directly to lymphocyte destruction (70). These agents appear to have a potential 
negative impact on the immune system response. 
Thiopental and methohexital have other concerning attributes. Methohexital has been linked 
to laryngospasm (68). Both medications have been connected to bronchospasm and are not 
recommended for patients with asthma (50,65,68,71). Both these agents are contraindicated 
in cases of porphyria. The medications may increase the activity of γ-aminolevulinic acid 
synthetase and precipitate an acute episode (50,68). 
These agents for multiple reasons do not appear to be ideal induction agents for severe 
sepsis and septic shock patients. Of note, thiopental is not manufactured in the United States 
as of 2011. 
4.6. Dexmedetomidine 
Dexmedetomidine is a newer sedative medication under investigation as an adjunct to 
intubation. It is currently approved primarily for sedation of critically ill patients in the 
intensive care environment. As it is a potential intubation facilitator, it will be mentioned in 
this chapter. It has many potential pitfalls that do not make it ideal for use in severe sepsis 
and septic shock. 
Dexmedetomidine is a centrally acting alpha-2 agonist with sedative, amnestic, and 
sympatholytic properties. It has the additive effect of preserving airway reflexes (72-74). 
Due to these properties, it is under evaluation as an adjunct for awake fiberoptic intubation 
(73).  
As an induction agent, dexmedetomidine is not as rapid as the other discussed agents. Use 
in the intubating environment requires a bolus of 0.5-1 mcg/kg over 10 minutes (73-75). An 
infusion follows ranging from 0.2-0.7 mcg/kg/hour until the procedure is complete (73, 75). 
This is not consistent with the rapid acting agents previously discussed. The medication 
does offers a significant degree of sedation, comfort and airway protection. For the 
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particularly high-risk airway, this drug creates an environment of “cooperative anesthesia” 
and has been shown to facilitate the awake intubation (73). The medication again is not as 
short acting as other medications reviewed. Onset of action is in 5-10 minutes and duration 
of action extends from 60-120 minutes. When time is critical, dexmedetomidine nay not fit 
the best pharmacologic profile 
Dexmedetomidine is metabolized through the hepatic system. Unlike several of the 
previously described agents, drug clearance is impacted by hepatic failure and low hepatic 
blood flow. Elimination is through renal and fecal routes (74). In regards to metabolism, 
elderly patients have been found to be particularly sensitive to dexmedetomidine. 
Reduction of bolus dosing in this population is encouraged (74).  
As an alpha-2 agonist, dexmedetomidine causes a decrease in mean arterial blood pressure 
and heart rate. Of note, With the initial bolus, a transient increase of mean arterial pressure 
can occur (50,74). This is felt to be due to a temporary stimulation of peripheral alpha-2 
receptors (50,74). Overall, dexmedetomidine reduces MAP, SVR, cardiac index and heart 
rate. These attributes are dose dependent and have been diminished with dose reduction or 
elimination of bolus administration. Dexmedetomidine has been linked to sinus arrest 
during intubation (74). In a hemodynamically, volume depleted, or inotropically challenged 
patient this side effect profile is not helpful. As severe sepsis and septic shock patients have 
many of these attributes, dexmedetomidine may not be the best induction option. 
Dexmedetomidine does deserve mention, as it is becoming a select option for induction and 
sedation. Dexmedetomidine preserves airway integrity, ventilatory response and reduces 
risk of bronchconstriction (74). In a tenuous airway situation, such qualities are clearly 
favorable.  
While not a first line induction choice, dexmedetomidine may have a role in the sedation of 
sepsis patients under the appropriate circumstances. Dexmedetomidine appears to have 
anti-inflammatory properties. In one study, the use of dexmedetomidine reduced the serum 
levels of tumor necrosis factor (TNF), interleukin-1 and interleukin-6 in comparison to 
midazolam (76). Use of dexmedetomidine as a sedative agent in another case study reduced 
delirium, ventilator days, and 28-day mortality in comparison to lorazepam (77). While the 
medication may not be an optimal emergency intubation agent, future avenues in its use as 
a sedative are intriguing. 
4.7. Methoxycarbonyl-etomidate (MOC-etomidate) and carboetomidate 
Etomidate as discussed has a very favorable profile in regards to use in severe sepsis and 
septic shock. The controversy ensues in regard to etomidate’s tendency to suppress the 
adrenal axis (31-32). In the interest of remaining up to date, it is important to mention 
etomidate analogues that may resolve the adrenal suppression debate. 
Methoxycarbonyl-etomidate is an ultra short-acting analogue of etomidate (78). It was 
designed to maintain the favorable hemodynamic profile of etomidate and avoid the 
adrenal axis suppression component. Like etomidate, MOC-etomidate does act at the GABA 
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receptor. In recent animal studies, this medication exhibited similar sedative potency and 
was found to have a half-life of 4 minutes as opposed to 40 minutes for etomidate (78). In 
initial promising research, the drug did not impact adrenal function. This may be due to its 
extremely swift onset and metabolism. There was some decreased potency in comparison to 
etomidate and its ultra rapid action will be a factor in future dosing. Multiple questions 
remain and this data remains extremely preliminary. It is important for the clinician to be 
aware of the next generation of agents. 
Carboetomidate is another analog designed for a better side effect profile as well. 
Carboetomidate generation focused specifically on adrenal suppression issues (79). The 
medication was designed to have a reduced affinity for 11 β–hydroxylase. This particular 
analog maintained a similar hypnotic effect to etomidate, a stable hemodynamic profile, and 
had a third less adrenal suppression activity. It also did have a slightly less hypnotic effect 
in regards to etomidate (79). Carboetomidate remains another future potential agent in the 
care of critically ill patients. Clearly, ongoing research is required. 
5. Conclusions 
As reviewed, endotracheal intubation of the critically ill septic patient is one of the most 
significant challenges an emergency medicine or critical care practitioner will face. The 
intubation procedure itself is associated with profound physiologic changes. Performing this 
procedure on a patient with underlying hemodynamic, respiratory, and additional organ 
compromise can be arduous. Agents to rapidly and safely accomplish this procedure need 
to be chosen. The caregiver needs to be aware of induction agent side effects, mechanism of 
action, metabolism, and duration of action. This knowledge is as important as the actual 
procedural skill. Intubation under adverse circumstances can be worsened with poor choice 
in induction mediator. 
Severe sepsis and septic shock is a particularly special circumstance. Critically ill septic 
patients are literally a maelstrom of organ failure. Induction mediators can help or hinder an 
already difficult task. This chapter is designed to facilitate the best choices for this particular 
patient care scenario. 
In review of induction medications, rapid onset with short duration of action, preservation 
of hemodynamic parameters, and low adverse side effect profile are key components for 
success. Table 1 summarizes the qualities of the previously discussed agents. For severe 
sepsis and septic shock, two particular candidates rise to the occasion. Ketamine and 
etomidate appear to be the best current induction options. 
The recommendation of etomidate may elicit some controversy. The adrenal suppression 
effect of this medication is well described in the literature. At the same time, multiple 
studies continue to show a paucity in mortality impact. The endocrine suppression is 
evident. The mortality figures are not. For rapid, reliable induction without hemodynamic 
compromise in a critical moment, etomidate does serve this purpose. Future agents and 
analogues may make this controversy obsolete.  
 
Induction Agents for Endotracheal Intubation in Severe Sepsis and Septic Shock 405 
 
MAP- Mean arterial pressure, SVR- Systemic vascular resistance, CI- Cardiac index, SV- Stroke volume 
Table 1. Summary of Induction Agent Attributes 
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Ketamine is another agent that appears well suited for induction of the severe sepsis and 
septic shock patient. Ketamine preserves airway reflexes, increases blood pressure and 
systemic vascular resistance, and serves as a bronchodilator. In a prospective trial, ketamine 
and etomidate exhibited a similar safety profile for a wide range of critically ill patients; 
including patients with sepsis (41). Due to increased myocardial oxygen consumption, 
ketamine may be a less optimal choice for patients with known coronary artery disease. 
All other agents discussed suppress the hemodynamic profile to some degree. Best choice 
for intubation induction for severe sepsis and septic shock remains etomidate and ketamine. 
Circumstances may preclude the use of these agents. The practicing clinician is cautioned to 
review the remaining sedation agents carefully in the context of the clinical picture. In the 
case that the need arises for another drug choice, the most rapid acting medication with the 
least duration of action and least adverse side effect profile should be administered. The 
informed clinician needs to be aware of the side effect profile and prepare accordingly. 
Successful intubation in severe sepsis and septic shock patients is a critical skill. Choosing 
the best medication to accomplish this task is a significant component of the battle. The well-
informed practitioner can make all the difference in this challenging situation.  
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